201 related articles for article (PubMed ID: 34002044)
1. LncRNA MAGI2-AS3 inhibits tumor progression and angiogenesis by regulating ACY1 via interacting with transcription factor HEY1 in clear cell renal cell carcinoma.
Wang G; Li H; Hou Y
Cancer Gene Ther; 2022 May; 29(5):585-596. PubMed ID: 34002044
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MAGI2-AS3 inhibites tumor progression by up-regulating STAM via interacting with miR-142-3p in clear cell renal cell carcinoma.
Yang R; Chen Z; Ao S; Liang L; Chen Z; Duan X; Zeng G; Deng T
Cell Signal; 2024 Jan; 113():110954. PubMed ID: 38084836
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNA MAGI2-AS3 Represses Cell Progression in Clear Cell Renal Cell Carcinoma by Modulating the miR-629-5p/PRDM16 Axis.
Yan C; Wang P; Zhao C; Yin G; Meng X; Li L; Cai S; Meng B
Crit Rev Eukaryot Gene Expr; 2023; 33(7):43-56. PubMed ID: 37602452
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA MAGI2-AS3/miR-218-5p/GDPD5/SEC61A1 axis drives cellular proliferation and migration and confers cisplatin resistance in nasopharyngeal carcinoma.
Cao C; Zhou S; Hu J
Int Forum Allergy Rhinol; 2020 Aug; 10(8):1012-1023. PubMed ID: 32450008
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA MAGI2-AS3 inhibits bladder cancer progression through MAGI2/PTEN/epithelial-mesenchymal transition (EMT) axis.
Shen D; Xu J; Cao X; Cao X; Tan H; Deng H
Cancer Biomark; 2021; 30(2):155-165. PubMed ID: 33104021
[TBL] [Abstract][Full Text] [Related]
6. Hypermethylation-Mediated lncRNA MAGI2-AS3 Downregulation Facilitates Malignant Progression of Laryngeal Squamous Cell Carcinoma via Interacting With SPT6.
Wang J; Yang C; Cao H; Yang J; Meng W; Yu M; Yu L; Wang B
Cell Transplant; 2023; 32():9636897231154574. PubMed ID: 36852700
[TBL] [Abstract][Full Text] [Related]
7. lncRNA MAGI2-AS3 suppresses castration-resistant prostate cancer proliferation and migration via the miR-106a-5p/RAB31 axis.
Yang G; Li T; Liu J; Quan Z; Liu M; Guo Y; Wu Y; Ou L; Wu X; Zheng Y
Genomics; 2023 Mar; 115(2):110599. PubMed ID: 36889366
[TBL] [Abstract][Full Text] [Related]
8. LncRNA MAGI2-As3 Suppresses the Proliferation and Invasion of Cervical Cancer by Sponging MiR-15b.
Chai Y; Wang L; Qu Y; Hu Z
J Healthc Eng; 2022; 2022():9707206. PubMed ID: 35126958
[TBL] [Abstract][Full Text] [Related]
9. LncRNA MAGI2-AS3 Inhibits Prostate Cancer Progression by Targeting the miR-142-3p.
Hu R; Wu P; Liu J
Horm Metab Res; 2022 Nov; 54(11):754-759. PubMed ID: 35944561
[TBL] [Abstract][Full Text] [Related]
10. LncRNA MAGI2-AS3 is downregulated in non-small cell lung cancer and may be a sponge of miR-25.
Sui Y; Chi W; Feng L; Jiang J
BMC Pulm Med; 2020 Mar; 20(1):59. PubMed ID: 32138716
[TBL] [Abstract][Full Text] [Related]
11. LncRNA MAGI2-AS3 inhibits hepatocellular carcinoma cell proliferation and migration by targeting the miR-374b-5p/SMG1 signaling pathway.
Yin Z; Ma T; Yan J; Shi N; Zhang C; Lu X; Hou B; Jian Z
J Cell Physiol; 2019 Aug; 234(10):18825-18836. PubMed ID: 30924168
[TBL] [Abstract][Full Text] [Related]
12. LncRNA MAGI2-AS3 inhibits bladder cancer progression by targeting the miR-31-5p/TNS1 axis.
Tang C; Cai Y; Jiang H; Lv Z; Yang C; Xu H; Li Z; Li Y
Aging (Albany NY); 2020 Nov; 12(24):25547-25563. PubMed ID: 33231563
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MAGI2-AS3 is downregulated in the distant recurrence of hepatocellular carcinoma after surgical resection and affects migration and invasion via ROCK2.
Fang G; Wang J; Sun X; Xu R; Zhao X; Shao L; Sun C; Wang Y
Ann Hepatol; 2020; 19(5):535-540. PubMed ID: 32546442
[TBL] [Abstract][Full Text] [Related]
14. LncRNA MAGI2-AS3 suppresses the proliferation and invasion of non-small cell lung carcinoma through miRNA-23a-3p/PTEN axis.
Hao XZ; Yang K
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7399-7407. PubMed ID: 31539127
[TBL] [Abstract][Full Text] [Related]
15. MAGI2-AS3 rs7783388 polymorphism contributes to colorectal cancer risk through altering the binding affinity of the transcription factor GR to the MAGI2-AS3 promoter.
Yang X; Wu S; Li X; Yin Y; Chen R
J Clin Lab Anal; 2020 Oct; 34(10):e23431. PubMed ID: 32533587
[TBL] [Abstract][Full Text] [Related]
16. Targeting MAGI2-AS3-modulated Akt-dependent ATP-binding cassette transporters as a possible strategy to reverse temozolomide resistance in temozolomide-resistant glioblastoma cells.
Chen Z; Zhou J; Liu Y; Ni H; Zhou B
Drug Dev Res; 2023 Nov; 84(7):1482-1495. PubMed ID: 37551766
[TBL] [Abstract][Full Text] [Related]
17. Long noncoding RNA MAGI2-AS3 regulates CCDC19 expression by sponging miR-15b-5p and suppresses bladder cancer progression.
Wang F; Zu Y; Zhu S; Yang Y; Huang W; Xie H; Li G
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):231-235. PubMed ID: 30442369
[TBL] [Abstract][Full Text] [Related]
18. MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2.
Xu X; Yuan X; Ni J; Guo J; Gao Y; Yin W; Li F; Wei L; Zhang J
J Cell Physiol; 2021 Feb; 236(2):1116-1130. PubMed ID: 32730644
[TBL] [Abstract][Full Text] [Related]
19. MAGI2-AS3 suppresses MYC signaling to inhibit cell proliferation and migration in ovarian cancer through targeting miR-525-5p/MXD1 axis.
Chang H; Zhang X; Li B; Meng X
Cancer Med; 2020 Sep; 9(17):6377-6386. PubMed ID: 32681706
[TBL] [Abstract][Full Text] [Related]
20. LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia.
Chen L; Fan X; Zhu J; Chen X; Liu Y; Zhou H
RNA Biol; 2020 Jun; 17(6):784-793. PubMed ID: 32174258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
